In the TGF-β signaling pathway, E2F5 status was reported to improve the diagnosis of the malignancy of breast tumors [80], epithelial ovarian cancer [81], and hepatocellular carcinoma [82]. This evidence concerns the gene E2F5 and hepatocellular carcinoma.